Institutional shares held 223 Million
1.63M calls
1.47M puts
Total value of holdings $114B
$829M calls
$747M puts
Market Cap $131B
256,691,008 Shares Out.
Institutional ownership 86.98%
# of Institutions 1,804


Latest Institutional Activity in VRTX

Top Purchases

Q1 2025
Manning & Napier Advisors LLC Shares Held: 235K ($120M)
Q1 2025
Envestnet Asset Management Inc Shares Held: 470K ($240M)
Q1 2025
Congress Asset Management CO Shares Held: 188K ($95.6M)
Q1 2025
Mirae Asset Global Investments Co., Ltd. Shares Held: 143K ($73M)
Q1 2025
Teacher Retirement System Of Texas Shares Held: 127K ($64.6M)

Top Sells

Q1 2025
Gamma Investing LLC Shares Held: 5K ($2.55M)
Q1 2025
Assenagon Asset Management S.A. Shares Held: 208K ($106M)
Q1 2025
Massachusetts Financial Services CO Shares Held: 2.02M ($1.03B)
Q1 2025
Robeco Institutional Asset Management B.V. Shares Held: 146K ($74.4M)
Q1 2025
Vontobel Holding Ltd. Shares Held: 74.8K ($38.1M)

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.


Insider Transactions at VRTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
300K Shares
From 15 Insiders
Exercise of conversion of derivative security 15.9K shares
Grant, award, or other acquisition 285K shares
Sell / Disposition
311K Shares
From 25 Insiders
Open market or private sale 158K shares
Payment of exercise price or tax liability 148K shares
Bona fide gift 4.6K shares

Track Institutional and Insider Activities on VRTX

Follow VERTEX PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if
Any

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX